4/A: Pembroke & Partners LLC Increases Stake in Matinas BioPharma Holdings, Inc.

Pembroke & Partners LLC reports acquiring Series C Convertible Preferred Stock and Warrants in Matinas BioPharma Holdings, Inc., increasing its beneficial ownership.

Summary

• Pembroke & Partners LLC filed a Form 4/A with the SEC regarding changes in beneficial ownership of Matinas BioPharma Holdings, Inc. securities.
• On April 8, 2025, Pembroke acquired 492 shares of Series C Convertible Preferred Stock at $0.586 and 1,679,182 Warrants at $0.6446.
• These acquisitions were part of a Securities Purchase Agreement dated February 13, 2025, where Pembroke purchased an aggregate of 984 shares of Preferred Stock and 3,358,364 Warrants for $984,000.
• The Preferred Stock has a stated value of $1,000 per share and can be converted to Common Stock at a price of $0.6393 per share.
• Pembroke's voting power is capped at 23% of the outstanding Common Stock based on the Preferred Stock.
• There are limits on the number of Common Stock shares issuable upon conversion of the Preferred Stock (9.99%) and exercise of the Warrants (4.99%).

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the increased investment by Pembroke & Partners, suggesting confidence in Matinas BioPharma's prospects. However, the presence of warrants and convertible securities introduces some complexity and potential dilution.

Positives

• Pembroke & Partners LLC has increased its investment in Matinas BioPharma Holdings, Inc., indicating confidence in the company's future prospects.

Risks

• The limits on Common Stock shares issuable upon conversion of the Preferred Stock and exercise of the Warrants could restrict Pembroke's potential gains.

Future Outlook

The document does not contain specific forward-looking statements from the company itself, but the investment by Pembroke & Partners suggests a positive outlook.

Industry Context

This announcement reflects ongoing investment activity in the biopharmaceutical sector, where companies like Matinas BioPharma are attracting capital to fund research and development.

Comparison to Industry Standards

• Similar investments in comparable companies often involve convertible preferred stock and warrants to provide investors with both income and potential upside from stock appreciation.
• The specific terms of the agreement, such as the conversion price and warrant exercise price, are typical for this type of financing in the biotech industry.
• Comparable companies that have used similar financing structures include XOMA Corporation and Aeterna Zentaris Inc.

Stakeholder Impact

• Shareholders may view the increased investment positively, potentially leading to an increase in stock price.
• The company gains additional capital to fund its operations and research.

Key Dates

Keywords

Matinas BioPharma Holdings, Pembroke & Partners, Series C Convertible Preferred Stock, Warrants, Beneficial Ownership, SEC Form 4, Investment